Intermittent BRAF-inhibitor therapy is a feasible option: Report of a patient with metastatic melanoma

British Journal of Dermatology

Volumn 170, Issue 1, 2014, Pages 220-222

  Koop, A ^a   Satzger, I ^a   Alter, M ^a   Kapp, A ^a   Hauschild, A ^b   Gutzmer, R ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; DABRAFENIB; DACARBAZINE; TRAMETINIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; SULFONAMIDE;

ARTHRALGIA; DRUG ERUPTION; DRUG INTERMITTENT THERAPY; FATIGUE; HUMAN; LETTER; METASTATIC MELANOMA; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SKIN TUMOR; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; CASE REPORT; DRUG ADMINISTRATION; GENETICS; MALE; MELANOMA; SECONDARY; SKIN NEOPLASMS; VERY ELDERLY;

AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; INDOLES; MALE; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF; SKIN NEOPLASMS; SULFONAMIDES;

EID: 84892399771     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12615     Document Type: Letter

References (10)

1. Chapman PB, Hauschild A, Robert C, et al,. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507-16.
2. Hauschild A, Grob JJ, Demidov LV, et al,. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65.
3. Villanueva J, Vultur A, Herlyn M,. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res 2011; 71: 7137-40.
4. Easty DJ, Gray SG, O'Byrne KJ, et al,. Receptor tyrosine kinases and their activation in melanoma. Pigment Cell Melanoma Res 2011; 24: 446-61.
5. Nazarian R, Shi H, Wang Q, et al,. Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation. Nature 2010; 468: 973-7.
6. Vultur A, Villanueva J, Herlyn M, et al,. Targeting BRAF in advanced melanoma: a first step towards manageable disease. Clin Cancer Res 2011; 17: 1658-63.
7. Villanueva J, Vultur A, Lee JT, et al,. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010; 18: 683-95.
8. Flaherty KT, Infante JR, Daud A, et al,. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012; 367: 1694-703.
9. Das Thakur M, McMahon M, Stuart DD, et al,. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-5.
10. Seghers AC, Wilgenhof S, Lebbé C, et al,. Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor. Melanoma Res 2012; 22: 466-72.